Short Interest in CapsoVision, Inc. (NASDAQ:CV) Decreases By 57.4%

CapsoVision, Inc. (NASDAQ:CV) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totaling 93,892 shares, a decline of 57.4% from the December 31st total of 220,233 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily volume of 536,493 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 536,493 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.2% of the company’s stock are sold short.

CapsoVision Stock Down 7.4%

Shares of NASDAQ CV traded down $0.40 during midday trading on Friday, reaching $5.02. 347,634 shares of the company were exchanged, compared to its average volume of 505,604. The stock’s 50-day moving average price is $8.45 and its 200-day moving average price is $5.84. The stock has a market cap of $235.14 million and a P/E ratio of -2.29. CapsoVision has a one year low of $3.43 and a one year high of $15.37.

CapsoVision (NASDAQ:CV) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The firm had revenue of $3.54 million during the quarter.

Institutional Trading of CapsoVision

A hedge fund recently bought a new stake in CapsoVision stock. New York State Common Retirement Fund purchased a new stake in shares of CapsoVision, Inc. (NASDAQ:CV) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 7,114 shares of the company’s stock, valued at approximately $34,000.

Analyst Upgrades and Downgrades

CV has been the topic of several recent research reports. Roth Mkm set a $7.00 price target on shares of CapsoVision in a research note on Tuesday, November 4th. Zacks Research upgraded CapsoVision to a “hold” rating in a report on Wednesday, November 5th. Benchmark reiterated a “speculative buy” rating on shares of CapsoVision in a report on Friday, November 14th. Wall Street Zen raised CapsoVision to a “hold” rating in a research report on Saturday, January 10th. Finally, Weiss Ratings reaffirmed a “sell (e)” rating on shares of CapsoVision in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $6.00.

About CapsoVision

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.